PsiOxus Therapeutics Ltd. says it has adequate funds for the moment after a freshly earned $15m milestone from partner Bristol-Myers Squibb Co – but its ambitions to move forward with its novel pipeline will send the firm back to investors for a Series D Financing to raise around $50m in the first half of 2018.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?